Atrial cellular electrophysiological changes in patients with ventricular dysfunction may predispose to AF

Heart Rhythm. 2009 Apr;6(4):445-51. doi: 10.1016/j.hrthm.2008.12.028. Epub 2008 Dec 31.

Abstract

Background: Left ventricular systolic dysfunction (LVSD) is a risk factor for atrial fibrillation (AF), but the atrial cellular electrophysiological mechanisms in humans are unclear.

Objective: This study sought to investigate whether LVSD in patients who are in sinus rhythm (SR) is associated with atrial cellular electrophysiological changes that could predispose to AF.

Methods: Right atrial myocytes were obtained from 214 consenting patients in SR who were undergoing cardiac surgery. Action potentials or ion currents were measured using the whole-cell-patch clamp technique.

Results: The presence of moderate or severe LVSD was associated with a shortened atrial cellular effective refractory period (ERP) (209 +/- 8 ms; 52 cells, 18 patients vs 233 +/- 7 ms; 134 cells, 49 patients; P <0.05); confirmed by multiple linear regression analysis. The left ventricular ejection fraction (LVEF) was markedly lower in patients with moderate or severe LVSD (36% +/- 4%, n = 15) than in those without LVSD (62% +/- 2%, n = 31; P <0.05). In cells from patients with LVEF <or= 45%, the ERP and action potential duration at 90% repolarization were shorter than in those from patients with LVEF > 45%, by 24% and 18%, respectively. The LVEF and ERP were positively correlated (r = 0.65, P <0.05). The L-type calcium ion current, inward rectifier potassium ion current, and sustained outward ion current were unaffected by LVSD. The transient outward potassium ion current was decreased by 34%, with a positive shift in its activation voltage, and no change in its decay kinetics.

Conclusion: LVSD in patients in SR is independently associated with a shortening of the atrial cellular ERP, which may be expected to contribute to a predisposition to AF.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Action Potentials
  • Angiotensin II Type 1 Receptor Blockers / therapeutic use
  • Angiotensin-Converting Enzyme Inhibitors / therapeutic use
  • Atrial Fibrillation / etiology*
  • Atrial Fibrillation / physiopathology*
  • Calcium Channel Blockers / therapeutic use
  • Chi-Square Distribution
  • Female
  • Heart Atria / cytology
  • Heart Atria / physiopathology
  • Humans
  • Linear Models
  • Male
  • Middle Aged
  • Myocytes, Cardiac / physiology*
  • Patch-Clamp Techniques
  • Potassium Channels / metabolism
  • Risk Factors
  • Ventricular Dysfunction, Left / complications*
  • Ventricular Dysfunction, Left / drug therapy
  • Ventricular Dysfunction, Left / physiopathology*
  • Ventricular Dysfunction, Left / surgery

Substances

  • Angiotensin II Type 1 Receptor Blockers
  • Angiotensin-Converting Enzyme Inhibitors
  • Calcium Channel Blockers
  • Potassium Channels